iShares MSCI Hong Kong ETF vs Immunovant Inc. Common Stock — how do they compare? iShares MSCI Hong Kong ETF trades at $21.72 (market cap $1.15B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Immunovant Inc. Common Stock is far larger — about 5.8× iShares MSCI Hong Kong ETF's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Immunovant Inc. Common Stock for 0 Days on average.
| EWH | IMVT | |
|---|---|---|
Market Cap | $1.15B | $6.62B |
Volume | 2,444,357 | 1,131,364 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $44.96 |
52-Week Low | $20.66 | $17.03 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $5.72B |
Signals from Pluang's Aura AI — not financial advice
EWH trades at $21.58, down 0.19% with a bearish technical signal as moving averages show strong selling pressure. The ETF tracks Hong Kong's Hang Seng Index, which has faced significant volatility due to US-China tensions and Federal Reserve policy concerns. Recent institutional selling by Empowered Funds LLC (70.2% reduction in Q2 2026) reflects cautious sentiment toward Hong Kong markets.
Outlook remains challenged by geopolitical risks and Hong Kong market volatility, though oversold RSI levels suggest potential for near-term technical bounce. Key risks include continued US-China tensions and Fed policy uncertainty, while opportunities exist if Hong Kong equities stabilize. The ETF lacks fundamental metrics as it tracks an index rather than operating as a standalone company.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →